🇺🇸 PLX3397 in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 2
Most-reported reactions
- Drug Reaction With Eosinophilia And Systemic Symptoms — 1 report (50%)
- Myocardial Infarction — 1 report (50%)
Frequently asked questions
Is PLX3397 approved in United States?
PLX3397 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for PLX3397 in United States?
Daiichi Sankyo Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.